Proton-irradiated breast cells: molecular points of view by Bravat&#224 et al.
Journal of Radiation Research, Vol. 60, No. 4, 2019, pp. 451–465
doi: 10.1093/jrr/rrz032
Advance Access Publication: 28 May 2019
Proton-irradiated breast cells: molecular
points of view
Valentina Bravatà1,†, Francesco P. Cammarata1,†, Luigi Minafra1,*,
Pietro Pisciotta1,2, Concetta Scazzone3, Lorenzo Manti4, Gaetano Savoca1,
Giada Petringa1,2, Giuseppe A.P. Cirrone2, Giacomo Cuttone2,
Maria C. Gilardi1,5, Giusi I. Forte1 and Giorgio Russo1
1Istituto di Bioimmagini e Fisiologia Molecolare-Consiglio Nazionale delle Ricerche (IBFM-CNR), Cefalù (PA), Italy
2National Institute for Nuclear Physics, Laboratori Nazionali del Sud, INFN-LNS, Catania, Italy
3Department of Biopathology and Medical Biotechnology, Palermo University, Palermo, Italy
4Department of Physics, University of Naples Federico II, via Cintia, I-80126 Naples, Italy
5Nuclear Medicine, San Raffaele Scientific Institute, Milan, Italy
*Corresponding author: Istituto di Bioimmagini e Fisiologia Molecolare-Consiglio Nazionale delle Ricerche (IBFM-CNR), Contrada Pietrapollastra Pisciotto,
90015 Cefalù (PA), Italy. Tel/Fax: +39 0921920612/510; Email: luigi.minafra@ibfm.cnr.it
†These authors contributed equally to this work
(Received 9 January 2019; revised 15 March 2019; editorial decision 19 April 2019)
ABSTRACT
Breast cancer (BC) is the most common cancer in women, highly heterogeneous at both the clinical and
molecular level. Radiation therapy (RT) represents an efficient modality to treat localized tumor in BC care,
although the choice of a unique treatment plan for all BC patients, including RT, may not be the best option.
Technological advances in RT are evolving with the use of charged particle beams (i.e. protons) which, due to a
more localized delivery of the radiation dose, reduce the dose administered to the heart compared with conven-
tional RT. However, few data regarding proton-induced molecular changes are currently available. The aim of
this study was to investigate and describe the production of immunological molecules and gene expression pro-
files induced by proton irradiation. We performed Luminex assay and cDNA microarray analyses to study the
biological processes activated following irradiation with proton beams, both in the non-tumorigenic MCF10A
cell line and in two tumorigenic BC cell lines, MCF7 and MDA-MB-231. The immunological signatures were
dose dependent in MCF10A and MCF7 cell lines, whereas MDA-MB-231 cells show a strong pro-inflammatory
profile regardless of the dose delivered. Clonogenic assay revealed different surviving fractions according to the
breast cell lines analyzed. We found the involvement of genes related to cell response to proton irradiation and
reported specific cell line- and dose-dependent gene signatures, able to drive cell fate after radiation exposure.
Our data could represent a useful tool to better understand the molecular mechanisms elicited by proton irradi-
ation and to predict treatment outcome
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INTRODUCTION
The idea that genes may function as biomarkers of disease response
provides the rationale for the development of molecularly based sig-
natures to predict response to radiation treatment in cancer, includ-
ing breast cancer (BC). Moreover, microarray-based expression
studies have demonstrated their relevance in the comprehension of
cancer behavior as well as in cancer care. It is well known that BC is
the most common cancer in women, highly heterogeneous at both
the clinical and molecular level and showing distinct subtypes asso-
ciated with different clinical outcomes; hence the need to develop
targeted therapeutic strategies [1, 2]. Gene expression profile (GEP)
studies allowed BC patients to be divided into clinically relevant sub-
types because of their distinct gene expression patterns, associated
with different prognoses. In turn, successful applications of specific
© The Author(s) 2019. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which
permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
• 451
D
ow
nloaded from
 https://academ
ic.oup.com
/jrr/article-abstract/60/4/451/5499294 by M
assim
o D
enaro user on 18 O
ctober 2019
molecularly based signatures in BC care were reported by the devel-
opment of specific assays, such as OncotypeDx, MammaPrint and
Prosigna, which have revolutionized the decision-making process on
the necessity of an adjuvant chemotherapy in BC patients [3].
Ionizing radiation (IR) delivered during radiation therapy (RT)
plays a key role in the therapeutic treatments for many types of can-
cer, including BC. Although technological advances in radiation
delivery have decisively enhanced treatment efficacy, the current
scenario still presents standard RT schedules that do not take into
account the specific molecular subtypes of patients with cancer in
the same anatomic position (such as breast, prostate, etc.) [4].
However, it is now well known that tumor heterogeneity, in terms
of both clinical and molecular characteristics, strongly affects treat-
ment outcome. Indeed, tumor radiosensitivity also depends on
many factors linked to biological characteristics. For example, in
BC, cell fate after radiation exposure depends on many factors such
as hormone receptor status (estrogen and progesterone receptors,
and human epidermal growth factor receptor 2), the number of
tumor cancer stem cells present before initiation of RT and their
ability to repopulate during the course of RT, effects of the tumor
microenvironment such as hypoxia, stromal interaction and varia-
tions in the intrinsic sensitivity of cells to radiation, modulation of
DNA repair or other cell survival pathways [5–8].
Thus, the choice of a unique RT plan, common to all BC
patients, may not be the best option. In addition, the advent of
hadrontherapy, particularly with the use of accelerated proton
beams, has led to a number of potential advantages over conven-
tional (photon/electron-based) RT for cancer, the most important
of which is arguably a more localized delivery of the radiation dose
with the consequent sparing of healthy tissues and/or organs at risk
[9–13]. In BC treatment, the prospective use of proton therapy in
place of conventional RT would result in a lower radiation dose to
the heart and lungs, especially if the tumor is located in the left
breast [14, 15]. Because of such advantages and due to clinically
encouraging results, proton therapy is currently used for several can-
cers and its use is rapidly growing [https://www.ptcog.ch/index.
php/facilities-in-operation, accessed June 2018].
However, few data are available regarding proton-induced
molecular changes, particularly in breast cells, a topic that therefore
deserves to be accurately described.
In addition, based on our previous findings, IR exposures could
stimulate the secretion of numerous inflammatory factors, which
can affect cell fate via multiple pathways and may thus influence
tumor progression control and the overall therapy outcome [16–
20]. These secreted factors may also interact with surrounding cells
and, hence, may damage unirradiated tissue via the bystander effect
[17]. To our knowledge, the immunological response of BC after
proton irradiation has yet to be investigated. Thus, the identification
of specific proton irradiation prognostic biomarkers and gene signa-
tures, predictive of RT efficacy, is of great usefulness in future clin-
ical practice. Equally important, the choice of an appropriate RT
treatment plan, based also on the knowledge of biological features
of the tumors to be treated, is necessary in order to increase the
chances of success [3].
In this scenario, the aim of this study was to describe the dose–
response effects on cell survival induced by proton beam irradiation
and, for the first time to our knowledge, the radiation-induced
GEPs and immunological molecules profiles produced by the
MCF10A mammary non-tumorigenic cell line, and MCF7 (not
metastatic, luminal, ER+/PR+/HER2−) and MDA-MB-231 (meta-
static, basal, triple negative) BC cell lines with different aggressive
phenotypes [21], after graded doses of proton irradiation. In par-
ticular, for the molecular investigations, three radiation doses were
selected based on the following criteria: 0.5 Gy to evaluate the
effects of low doses; 2 Gy as it represents the fractionated dose in
RT of breast cancer; 9 Gy to evaluate the effects of high doses also
to be compared with our previous studies on electron beams. [17,
22, 23]. Our results highlighted the global molecular and immuno-
logical response of tumorigenic and non-tumorigenic BC cell lines
to proton therapy.
MATERIALS AND METHODS
Proton irradiation set-up
Proton irradiations were performed using the 62 MeV proton beam
generated by the superconducting cyclotron clinically used at the
CATANA (Centro di AdroTerapia ed Applicazioni Nucleari
Avanzate) eye proton therapy facility of the Italian Institute for
Nuclear Physics in Catania, Italy [20–22]. The protons were accel-
erated by a superconductive cyclotron; the beam was converted into
a uniform clinical beam, according to the international guidelines,
able to cover the entire target region passing through different pas-
sive elements [24–26]. Flasks were irradiated in the upright position
facing the collimated beam exit by delivering separate shots to cover
the flask surface entirely; an ad-hoc remotely controlled positioning
system ensured that after each shot, the flask was moved so that the
next shot would hit the adjacent area. Uniformity in dose distribu-
tion and inter-shot reproducibility was routinely checked prior to
each experimental run using radiochromic films. Dosimetry was also
performed: the lateral beam profile was verified using a semicon-
ductor diode, while the depth dose profiles and dosimetric calibra-
tions were performed using a motorized Markus chamber within a
water tank. The dosimetric system was calibrated under reference
conditions defined by the International Atomic Energy Agency
Technical Reports Series No. 398 ‘Absorbed Dose Determination in
External Beam Radiotherapy’ [27]. Cell irradiations were conducted
placing the cells at the middle of the spread-out Bragg peak (SOBP,
1 cm width), to simulate a clinical condition, with dose values of
0.5, 2, 4, 6 and 9 Gy, and a dose rate of 15 Gy min–1.
Cell culture and clonogenic survival assay
The human non-tumorigenic breast epithelial MCF10A cell line and
the human breast adenocarcinoma MCF7 and MDA-MB-231 cell
lines were purchased from the American Type Culture Collection
(ATCC) and cultured according to the manufacturer’s instructions
(ATCC, Manassas, VA, USA) as previously reported [13]. Cells
were maintained in an exponentially growing state at 37°C in a 5%
CO2 incubator; 2 days before irradiation they were seeded in T25
tissue culture flasks at 3–5×105 cells per flask. Cell survival was eval-
uated by clonogenic assay performed as previously described [22,
23, 28]. Briefly, 24 h after irradiation, cells were detached, counted
by a hemocytometer and re-plated in triplicate at opportune
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densities according to the dose delivered (200–2000 cells per well)
in a 6-well plate to assay the surviving fraction (SF). Untreated cells
(basal) were used as control in order to evaluate the plating effi-
ciency (PE). Cells were allowed to form colonies under normal cell
culture conditions for 10–12 days and then were fixed and stained
for 30 min with 6% glutaraldehyde and 0.5% crystal violet (both
from Sigma-Aldrich, St. Louis, MO, USA). Colonies with >50 cells
were counted manually under a Zeiss Axiovert phase-contrast
microscope (Carl Zeiss, Göttingen, Germany). Dose–response data
shown in the graph of Fig. 1 are generated from the mean of three
independent experiments. The error bars for each cell sample are
on the x-axis for the dosimetric error and on the y-axis for the error
of the SFs calculated with the error propagation method.
Cytokine, chemokine and growth factor analysis by
Luminex
Cells were collected at 24, 48 and 72 h post-irradiation. Twenty-
four hours before irradiation, the growth medium was replaced with
fresh medium. At the above times after exposure, irradiated condi-
tioned medium (ICMs) was collected. For each cell line, one flask
with the same cell number compared with treated samples was
seeded and grown under the same experimental conditions. Thus,
their complete conditioned medium (CM) was collected and used
as control (basal, i.e. untreated). Complete media without cells were
incubated under the same experimental conditions and used as the
blank controls. CM and ICM were stored at −80°C until use.
Immediately before the cytokine assay, thawed samples were centri-
fuged at 12 000 rpm for 5–10 min to allow precipitation of any lipid
excess and tested for the following panel of 17 cytokines, chemo-
kines and growth factors: interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6,
IL-7, IL-8, IL-10, IL-12(p70), IL-13, IL-17, interferon (IFN)-γ,
tumor necrosis factor (TNF)-α, monocyte chemoattractant protein-
1 (MCP-1), macrophage inflammatory protein-1β (MIP-1β), gran-
ulocyte–macrophage colony-stimulating factor (GM-CSF) and gran-
ulocyte colony-stimulating factor (G-CSF). The assay was carried
out using the Luminex system (BioRad, Munchen, Germany)
according to the manufacturer’s instructions, as previously described
[17]. The assay was performed using an eight-point standard curve
for every molecule. Data were evaluated using the Bio-Plex Manager
software (BioRad). Standards, internal controls and samples are cal-
culated as means of duplicate measurements. Data reported in
Tables 1, 2 and 3 for each time point correspond to normalized
values of expression levels. In particular, the means of duplicates for
each cytokine/time point of treated samples have been normalized
with respect to the means of duplicates for each cytokine of
untreated controls collected on the day of irradiation (time point
0). Furthermore, Supplementary file 2 contains a second-order poly-
nomial fitting analysis conducted for each immunological molecule,
in order to study their trend according to time and dose delivered.
Whole-genome cDNA microarray expression analysis
To study molecular pathways and cell networks activated at the
transcriptional level following proton beam irradiations, gene
expression experiments by cDNA microarray were conducted in
order to select potential new biomarkers of radiosensitivity and
radioresistance as previously described [22, 23]. Twenty-four hours
after irradiation with 0.5, 2 and 9 Gy, MCF10A, MCF7 and MDA-
MB-231 cell lines were harvested, counted and the pellet stored
immediately at −80°C. Total RNA was extracted from cells using
Trizol and the RNeasy mini kit according to the manufacturer’s
guidelines (Invitrogen). RNA concentration and purity were deter-
mined spectrophotometrically using a Nanodrop ND-1000
(Thermo Scientific Open Biosystems, Lafayette, CO, USA), and
RNA integrity, measured as RNA integrity number (RIN) values,
was assessed using a Bioanalyzer 2100 (Agilent Technologies, Santa
Clara, CA, USA). Only samples with a maximum RIN of 10 were
used for further microarray analysis. A 500 ng aliquot of total RNA
was used for conplementary RNA (RNA) synthesis and labeling
according to the Agilent Two-Color Microarray-Based Gene
Expression Analysis protocol. Samples were labeled with Cy5 dye
and control with Cy3 dye (Agilent Technologies). Fluorescent
cRNA samples (825 ng) were then hybridized onto Whole Human
Genome 4 × 44 K microarray GeneChips (Agilent Technologies)
containing all known genes and transcripts of an entire human gen-
ome. Six replicates were performed. Array hybridization was con-
ducted for 17 h at 65°C. Images were acquired with a DNA
Microarray Scanner with Sure Scan high-Resolution Technology
(Agilent Technologies). Statistical data analysis, background correc-
tion and normalization of the gene expression profiles (GEPs) were
performed using Feature Extraction and GeneSpring software GX
13.0 (Agilent Technologies). Specifically, data were filtered using a
two-step procedure: first the entities were filtered based on their
flag values P (present) and M (marginal) and then filtered based on
their signal intensity values, which enables very low signal values or
removal of those that have reached saturation. Statistically signifi-
cant differences were computed by Student’s t-test, and the signifi-
cance level was set at P < 0.05. The false discovery rate (FDR) was
used as a multiple test correction method. Genes were identified as
being differentially expressed if they showed a fold change (FC) of
at least 2 with a P-value < 0.05 compared with untreated MCF10A,
Fig. 1. Dose-dependent survival curves of MCF10A, MCF7
and MDA-MB-231 cells after proton irradiation with doses
of 0.5, 2, 4, 6 and 9 Gy at the therapeutic middle SOBP.
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Table 1. MCF10A cytokine, chemokine and growth factor profiles induced by proton treatments
MCF10A non-tumorigenic mammary epithelial cells
24 h 48 h 72 h
Analytes 0.5 Gy 2 Gy 9 Gy 0.5 Gy 2 Gy 9 Gy 0.5 Gy 2 Gy 9 Gy
IL-1β 0.78 0.69 0.81 0.94 0.95 1.34 1.08 1.17 1.69
IL-6 0.91 0.83 0.86 0.82 0.98 2.48 0.78 0.97 2.89
TNF-α 0.78 0.65 0.83 0.96 0.94 1.32 1.08 1.21 1.53
IL-12 0.29 0.11 0.47 0.64 0.29 1.00 0.64 0.64 1.18
IFN-γ 0.82 0.71 0.82 0.95 0.94 1.23 1.07 1.17 1.39
IL-4 0.80 0.74 0.84 0.97 0.96 1.27 1.09 1.19 1.49
IL-10 0.43 0.32 0.54 0.43 0.49 1.24 0.60 0.94 1.18
IL-13 0.77 1.00 0.77 0.77 0.77 1.00 0.77 1.00 1.23
IL-8 0.99 0.87 1.06 1.17 1.28 2.15 1.37 1.65 3.69
MCP-1 0.77 0.65 0.67 1.31 1.11 1.12 3.53 4.56 3.11
MIP-1β 0.18 0.00 0.33 0.84 0.56 2.01 1.30 1.64 2.82
IL-2 0.72 0.60 0.75 0.90 0.87 1.23 0.99 1.11 1.38
IL-7 0.66 0.48 0.66 1.00 0.77 1.16 1.32 1.32 1.27
IL-17 0.68 0.56 0.78 1.04 0.96 1.70 1.27 1.47 2.20
G-CSF 0.70 0.57 0.79 0.99 0.90 1.91 1.22 1.61 3.77
GM-CSF 0.90 0.86 0.86 1.02 1.02 1.29 1.10 1.10 1.39
IL-5 was undetectable.
Values (in term of pg ml–1) were normalized using CM of untreated MCF10A cells.
Table 2. MCF7 cytokine, chemokine and growth factor profile induced by proton treatments
MCF7 breast cancer cell line
24 h 48 h 72 h
Analytes 0.5 Gy 2 Gy 9 Gy 0.5 Gy 2 Gy 9 Gy 0.5 Gy 2 Gy 9 Gy
IL-6 1.18 1.29 1.25 1.67 1.64 3.33 3.62 4.31 7.36
TNF-α 0.38 0.69 1.00 0.69 0.84 0.69 0.69 1.00 1.33
IFN-γ 0 0 0 0 0.17 1.00 0 1.00 0
IL-8 0.77 0.59 1.45 0.91 1.23 1.45 2.00 2.55 3.50
MCP-1 0.00 0.00 0.11 0.40 1.00 1.00 3.26 2.56 0.00
IL-7 0.00 0.09 0.09 0.26 0.26 0.00 0.26 0.09 0.43
IL-17 0.80 0.54 0.80 1.07 0.66 0.80 1.34 1.46 0.93
GM-CSF 0.00 0.00 0.00 0.08 1.38 1.96 2.77 1.50 0.23
IL-2, IL-4, IL-5, IL-10, IL-12, IL-13, G-CSF, MIP-1b and IL-1β were undetectable.
Values (in term of pg ml–1) were normalized using CM of untreated MCF7 cells.
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MCF7 and MDA-MB-231 cell lines used as reference samples. As
described above, the same experimental approach was performed
for both cell lines used in this project. The data discussed in this
publication have been deposited in the National Center for
Biotechnology Information Gene Expression Omnibus (GEO) [29]
and are accessible through GEO Series accession numbers
(GSE116325 and GSE103472). Microarray data are available in
compliance with Minimum Information About a Microarray
Experiment (MIAME) standards.
Pathway analyses of GEP lists
Differentially expressed gene lists obtained by GEP analysis were ana-
lyzed using Reactome, a tool that provides a comprehensive set of
functional annotation for investigators to understand biological mean-
ing behind a large list of genes. Reactome is a free, open-source,
open-data, curated and peer-reviewed knowledge base of biomolecu-
lar pathways (https://reactome.org/). One of its main priorities is to
provide easy and efficient access to its high-quality curated data and
to provide intuitive bioinformatics tools for the visualization, inter-
pretation and analysis of pathway knowledge. It also provides a rapid
means to reduce large lists of genes into functionally related groups
of genes to help unravel the biological content captured by high-
throughput technologies such as microarray analyses [30].
PubMatrix
All genes assayed in this work were analyzed using the PubMatrix
tool, as previously described, in order to confirm our assumptions
and to study bibliographic relationships between proteins and some
selected queries such as IR, radiation, cancer, BC, proton, inflamma-
tion, cell cycle and apoptosis [31].
RESULTS
Cell survival
In order to test the effects of the proton beam irradiation on cell
loss of reproductive capacity, MCF10A non-tumorigenic mammary
epithelial cells, and MCF7 and MDA-MB-231 tumorigenic BC cell
lines were irradiated with the doses of 0.5, 2, 4, 6 and 9 Gy.
Dose–response effects were tested by clonogenic assay, and the
SFs obtained revealed varying cellular radiosensitivity according to
the breast cell lines analyzed (Fig. 1). In particular, the SFs follow-
ing exposure to doses of 0.5, 2 and 9 Gy are as follows: MCF10A
cells, 0.78 (± 0.08); 0.44 (± 0.09); 0.050 (± 0.09); MCF7 cells,
0.67 (± 0.13); 0.38 (± 0.15); 0.0385 (± 0.0007); and MDA-MB-
231 cells, 0.81 (± 0.11); 0.53 (± 0.10); 0.040 (± 0.01),
respectively.
Immunological molecule profiles secreted after radiation
treatment
We evaluated the relative expression of cytokines, chemokines and
growth factors produced by non-tumorigenic mammary epithelial
MCF10A cells and tumorigenic BC MCF7 and MDA-MB-231 cell
lines after proton irradiation with the doses of 0.5, 2 and 9 Gy and
assayed 24, 48 and 72 h after radiation exposures. The above-
mentioned immunological factors were chosen according to their
involvement in the cell radiation response, as described by several
authors and also by our group [16, 17]. The results of these assays
Table 3. MDA-MB-231 cytokine, chemokine and growth factor profiles induced by proton treatments
MDA-MB-231 breast cancer cell line
24 h 48 h 72 h
Analytes 0.5 Gy 2 Gy 9 Gy 0.5 Gy 2 Gy 9 Gy 0.5 Gy 2 Gy 9 Gy
IL-1β 1.00 1.28 1.44 5.00 5.28 7.68 7.04 11.84 17.92
IL-6 1.25 1.65 1.43 3.94 4.58 4.04 5.48 9.90 8.73
TNF-α 1.38 1.57 1.57 3.54 3.74 3.74 4.75 8.49 6.81
IFN-γ 0.00 0 0 8.74 10.31 10.31 18.55 40.23 36.28
IL-4 1.25 1.14 1.25 1.44 1.78 1.89 1.83 2.67 2.61
IL-13 0.13 0.00 0.13 0.00 0.13 0.13 0.13 0.13 0.25
IL-8 1.12 1.25 2.00 3.38 3.50 5.46 5.05 8.21 10.25
MCP-1 1.13 1.19 1.63 1.63 1.91 2.09 2.09 3.15 3.21
IL-7 1.00 1.25 1.63 1.25 1.50 1.56 1.63 2.33 2.21
G-CSF 1.11 1.57 1.82 3.65 4.32 5.18 4.99 9.63 9.20
GM-CSF 1.04 0.98 1.26 1.14 1.24 1.74 1.33 1.73 2.42
IL-2, IL-5, IL-10, IL-12, IL-17 and MIP-1b were undetectable.
Values (in term of pg ml–1) were nomralized using CM of untreated MDA-MB-231 cells.
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are displayed in Tables 1, 2 and 3. Furthermore, Supplementary file
2 contains a second-order polynomial fitting analysis conducted for
each immunological molecule, in order to study their trend accord-
ing to time and dose delivered.
Immunological molecule profiles secreted by the non-tumorigenic
breast MCF10A cell line
As shown in Table 1, 16 out of 17 immunological molecules investi-
gated were deregulated in MCF10A cells after proton irradiation,
compared with untreated cells. Only IL-5 levels fell below the
instrument detection threshold because of a too low secretion in
ICM.
In summary, as shown in Table 1 and in Supplementary file 2, a
slight increase of cytokine secretion was observed at 48 and 72 h
post-irradiation with low doses (0.5 and 2 Gy). However, a rapid
increase of all the molecules tested was observable starting from
48 h post-treatment after irradiation with the highest dose used, i.e.
9 Gy, describing a polynomial-type increasing trend of inflammatory
molecules (IL-1β, IL-6, TNF-α and IL-17), TH1-type (IL-12 and
IFN-γ), TH2-type (IL-4 and IL-10), chemokines (IL-8, MCP-1 and
MIP-1β) and growth factors (IL-2, G-CSF and GM-CSF). These
findings suggest a time- and dose-dependent secretion of immuno-
logical molecules. It is noteworthy that the first temporarily up-
regulated molecules, regardless of the dose delivered, are the two
chemokines IL-8 and MCP-1, for which the increase is observed as
early as 48 h post-treatment.
Immunological molecule profiles secreted by the breast cancer
MCF7 cell line
As regards the MCF7 BC cell line, Table 2 shows the cytokine, che-
mokine and growth factor signature for the three doses used (0.5, 2
and 9 Gy), at the chosen post-irradiation time points (24, 48 and
72 h). As displayed, only 8 out of the 17 immunological factors
assayed were detectable. In particular, the levels of IL-2, IL-4, IL-5,
IL-10, IL-12, IL-13, G-CSF, MIP-1β and IL-1β were undetectable
because of their too low secretion in ICM. These results are in line
with those recently described by Desai et al. regarding the minimal
secretion of immunological factors in the ICM by MCF7 cells com-
pared with other human cancer cell lines analyzed after radiation
exposure, also described by our group following electron radiation
treatments [17–20]. As shown in Table 2 and in Supplementary file
2, polynomial fitting analysis describes an irregular trend for many
of the assayed molecules. Only IL-6 and IL-8 seem to be produced
in a time- and dose- delivered-dependent manner. In particular, a
peak of release was highlighted in ICM for the pro-inflammatory
cytokine IL-6 and the chemokines IL-8 and MCP-1 72 h after pro-
ton irradiation, as these molecules were up-regulated by a 2-fold fac-
tor, compared with CM of untreated MCF7 cells.
Immunological molecule profiles secreted by the metastatic breast
cancer MDA-MB-231 cell line
As above described, the same Luminex experimental approach was
performed for proton-treated MDA-MB-231 BC cells. In detail,
Table 3 shows the relative expression of the immunological factors
released by cells at 24, 48 and 72 h post-proton irradiation using the
doses of 0.5, 2 and 9 Gy. As assayed, 11 out of 17 immunological
molecules investigated were deregulated in MDA-MB-231 cells after
irradiation, compared with the control. In fact, IL-5, IL-12, IL-10,
IL-2, MIP-1β and IL-17 were undetectable, because of their too low
secretion in ICM. As also shown in Table 3 and in Supplementary
file 2, with the exception of IL-13, all the other factors were up-
regulated in a time- and dose increase-dependent manner. Overall,
the immune response profile of MDA-MB-231 cells to irradiation
was characterized by an earlier activation of almost all the immuno-
logical factors found in the ICM; such an increase was evident
already 24 h post-treatment, with the exception of IFN-γ and IL-13,
becoming consistent especially after 48 and 72 h. These data suggest
a time-dependent cytokine signature; however, in the case of MDA-
MB-231, the dose effect is less evident, since even for the low doses
(0.5 and 2 Gy) there is a conspicuous secretion of the molecules
found in the ICM, except for IL-13, with a 3-fold increase for 6 out
12 molecules assayed (IL-1β, IL-6, TNF-α, IFN-γ, IL-8 and
G-CSF). Note that the IFN-γ, reached a value of 40.23 for the dose
of 2 Gy at the time point of 72 h post-treatment and 36.28 with
9 Gy at the same time point, suggesting the activation of a strong
TH1-type response. Overall, increased levels of IL-1β, IL-6, TNF-α,
IL-7 and IFN-γ (characterized by a pro-inflammatory behavior),
IL-8 and MCP-1 (chemokines) and G-CSF and GM-CSF (growth
factors) were observed, especially at 72 h post-treatment at all
radiation doses. Hence, MDA-MB-231 cells showed the strongest
potentially pro-inflammatory secretion profile compared with the
other cell types analyzed. Indeed, these cells produce a large spec-
trum of inflammatory molecules regardless of the dose delivered,
unlike MCF7 and MCF10 for which only IL-6, IL-8 and MCP-1
showed this peculiarity.
Overview of cDNA microarray gene expression and
pathway analysis
Non-tumorigenic breast MCF10A cell line
In this study, a two-color microarray-based gene expression analysis
was conducted on MCF10A cells 24 h post-irradiation with proton
beams using 0.5, 2 and 9 Gy of IR doses, compared with untreated
MCF10A cells, used as the reference sample. Comparative differen-
tial gene expression analysis revealed that multiple genes were sig-
nificantly altered, by ≥2-fold, compared with untreated cells as
follows: MCF10A 0.5 Gy, 615 differentially expressed genes (DEGs;
167 down-regulated and 448 up-regulated); MCF10A 2 Gy, 881
DEGs (224 down-regulated and 657 up-regulated); and MCF10A
9 Gy, 929 DEGs (319 down-regulated and 610-up regulated)
(Fig. 2).
Moreover, up- and down-regulated transcripts were selected and
grouped according to their involvement in specific biological path-
ways using the Reactome tool [30] as displayed in Tables 4, 5 and
6. The result of this mapping revealed the involvement of a set of
factors controlling cellular processes, such as gene transcription, cell
fate, immune response, cell adhesion, migration and cellular traffick-
ing, in comparison with the reference sample. In addition, the GEP
lists of MCF10A 0.5 Gy, MCF10A 2 Gy and MCF10A 9 Gy were
also analyzed by Venn diagrams in order to identify overlapping
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deregulated genes among all the configurations assayed in this work,
as shown in Fig. 2. Summarizing, in MCF10A cells, some common
genes were deregulated by proton irradiation between 0.5 and 2 Gy
(203 common genes), between 2 and 9 Gy (240 common genes)
and between 0.5 and 9 Gy (48 common genes). As shown in Venn
diagrams displayed in Fig. 2, some genes were deregulated in a
unique way according to the specific dose delivered, suggesting a
characteristic dose-dependent molecular response. A common gene
list could represent the chance for cells to respond in a common
way to irradiation, activating specific cell networks. Interestingly, 92
genes (Supplementary file 1) were deregulated after all the three
doses used, and with the same expression trend. Thus, we decided
to load this 92 gene signature into the Reactome tool in order to
select the top five statistically relevant biological pathways. Results
are provided in Table 7. In order to identify possible documented
relationships between 92 microarray gene expression lists and some
processes known to be involved in cell response to IR treatment,
we used the PubMatrix V2.1 tool. In this way, lists of terms, such as
protein names, can be assigned to a genetic, biological or clinical
relevance in a flexible systematic fashion in order to confirm our
assumptions. The common pathways activated in MCF10A, regard-
less of the used dose, involve networks related to inflammation, lipid
metabolism and detoxification processes, which are not involved in
death or cell fate balance, nor typically linked to the IR response.
MCF7 breast cancer cell line
The MCF7 BC cell line was exposed to proton beam irradiation
using 0.5, 2 and 9 Gy doses. As described above, the MCF7 cell line
response to proton irradiation was analyzed 24 h post-irradiation
using a two-color microarray-based gene expression approach. GEPs
of the MCF7 cell line exposed to 0.5, 2 and 9 Gy revealed that mul-
tiple genes had significantly altered their expression levels, by ≥2-
fold compared with the untreated MCF7 cells, used as reference
group: MCF7 0.5 Gy, 266 DEGs (97 down-regulated and 169 up-
regulated); MCF7 2 Gy, 506 DEGs (134 down-regulated and 291
Fig. 2. Venn diagram of microarray gene sets of
MCF10A cells exposed to 0.5, 2 and 9 Gy of proton
irradiation.
Table 4. Top five molecular pathways of deregulated gene data sets of MCF10A, MCF7 and MDA-MB-231 cells treated with
0.5 Gy
Pathway name Genes found in GEP list Entities (total) P-value FDR
MCF10A 1 Fatty acids 4 29 1.85E-2 7.21E-1
2 Activation of the phototransduction cascade 3 19 2.84E-2 7.21E-1
3 Relaxin receptors 2 8 3.14E-2 7.21E-1
4 cGMP effects 3 20 3.24E-2 7.21E-1
5 Glucagon-type ligand receptors 4 35 3.36E-2 7.21E-1
MCF7 1 Signal regulatory protein family interactions 3 16 2.01E-3 5.21E-1
2 GABA synthesis 1 2 3.02E-2 5.96E-1
3 ABC transporters in lipid homeostasis 2 18 3.16E-2 5.96E-1
4 GABA synthesis, release, reuptake and degradation 2 19 3.48E-2 5.96E-1
5 NR1D1 (REV-ERBA) represses gene expression 1 3 4.49E-2 5.96E-1
MDA-MB-231 1 ERBB2 activates PTK6 signaling 5 18 2.71E-3 8.39E-1
2 ERBB2 regulates cell motility 5 19 3.41E-3 8.39E-1
3 GRB2 events in ERBB2 signaling 5 20 4.23E-3 8.39E-1
4 Hydroxycarboxylic acid-binding receptors 3 7 6.07E-3 8.39E-1
5 Post-transcriptional silencing by small RNAs 3 7 6.07E-3 8.39E-1
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up-regulated); and MCF7 9 Gy, 604 DEGs (158 down-regulated
and 446 up-regulated) (Fig. 3).
Also in this case, up- and down-regulated transcripts were
selected and grouped according to their involvement in specific bio-
logical pathways using integrated pathway enrichment analysis with
Reactome, and the top significant pathways were analyzed for all
the configurations assayed (Table 4, 5 and 6).
The result of this mapping revealed involvement of a set of fac-
tors controlling specific cellular processes, such as inflammation,
response to drug, cell fate regulation and cellular trafficking in com-
parison with the reference sample. In addition, the GEP lists were
also analyzed by Venn diagrams in order to identify overlapping
deregulated genes among all the configuration assayed in this work,
as shown in Fig. 3. In proton-treated MCF7 BC cells, some com-
mon genes were deregulated between 0.5 and 2 Gy (32 common
genes), between 2 and 9 Gy (195 common genes) and between 0.5
and 9 Gy (25 common genes). Moreover, as displayed, 58 deregu-
lated genes were common between all the three configurations ana-
lyzed (Supplementary file 1).
We speculated that this 58 gene signature could be responsible
for the activation of intracellular mechanisms in response to
radiation-induced stress. This molecular response appears not to be
dependent on the specific dose delivered. Thus, we fed this gene
signature into the Reactome tool, but no statistically relevant
biological processes known to be related to cell response to radi-
ation were selected (Table 7). These pathways involve GABA (γ-
aminobutyric acid) metabolism, transduction signaling and gene
expression regulation.
MDA-MB-231 metastatic breast cancer cell line
As described above for MCF10A and MCF7 cell lines, the same
GEP approach with a two-color microarray-based gene expression
analysis was performed for MDA-MB-231 cells 24 h post-irradiation.
Comparative differential gene expression analysis revealed that mul-
tiple genes were significantly altered, by ≥2-fold, compared with
untreated cells as follows: MDA-MB-231 0.5 Gy, 959 DEGs (266
down-regulated and 693 up-regulated); MDA-MB-231 2 Gy, 1105
DEGs (328 down-regulated and 777 up-regulated); and MDA-MB-
231 9 Gy, 1429 DEGs (389 down-regulated and 1040 up-regulated)
(Fig. 4).
Also in this case, an integrated pathway enrichment analysis was
performed for all the configurations assayed. Summarized Reactome
data regarding the top five pathways are displayed in Tables 4, 5 and
6. The result of this mapping revealed involvement of a set of factors
controlling specific intracellular signaling belonging to ERBB2 path-
way apoptosis, gene transcription, and inflammatory and anti-
inflammatory pathways. In addition, the overlapping deregulated
Table 5. Top five molecular pathways of deregulated gene data sets of MCF10A, MCF7 and MDA-MB-231 cells treated with
2 Gy
Pathway name Genes found in
GEP list
Entities
(total)
P-value FDR
MCF10A 1 Interleukin-4 and 13 signaling 23 212 1.01E-3 7.22E-1
2 RUNX3 regulates immune response and cell migration 4 10 2.03E-3 7.22E-1
3 RUNX1 regulates transcription of genes involved in differentiation
of keratinocytes
4 11 2.85E-3 7.22E-1
4 Transcriptional activation of p53-responsive genes 3 6 4.03E-3 7.22E-1
5 Transcriptional activation of cell cycle inhibitor p21 3 6 4.03E-3 7.22E-1
MCF7 1 TP53 regulates transcription of death receptors and ligands 7 18 1.29E-6 8.42E-4
2 TP53 regulates transcription of cell death genes 11 83 4.14E-5 1.35E-2
3 Signal regulatory protein family interactions 5 18 2.08E-4 4.51E-2
4 Interaction between L1 and ankyrins 6 33 4.66E-4 7.6E-2
5 Transcriptional activation of cell cycle inhibitor p21 3 6 7.71E-4 8.33E-2
MDA-MB-
231
1 Activation of kainate receptors upon glutamate binding 6 34 1.57E-2 8.76E-1
2 RUNX1 regulates transcription of genes involved in differentiation
of keratinocytes
3 11 2.72E-2 8.76E-1
3 TNFs bind their physiological receptors 5 30 3.25E-2 8.76E-1
4 MET activates STAT3 2 5 3.49E-2 8.76E-1
5 Apoptosis-induced DNA fragmentation 3 13 4.13E-2 8.76E-1
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genes among all the configuration analyzed for MDA-MB-231 cells
were highlighted by Venn diagrams, as shown in Fig. 4. In proton-
treated MDA-MB-231 cells, some common genes were deregulated
between 0.5 and 2 Gy (195 common genes); 2 and 9 Gy (215 com-
mon genes); and 0.5 and 9 Gy (113 common genes). As shown in
Venn diagrams, 265 deregulated genes were common between all
the three configurations assayed (Supplementary file 1), and we
speculate that this gene signature could be responsible for the activa-
tion of intracellular mechanisms able overall to react to stress, such
those induced by IR. Also in this case, we decided to load this gene
signature into the Reactome tool which highlighted statistically rele-
vant biological processes activated by proton exposure, known to be
related to cell response to radiation, as displayed in Table 7. These
are involved in gene expression regulation, WNT signalling, inflam-
mation and glycogen metabolism.
Dose-related gene signature of BC cell lines
Finally, in order to evaluate the DEGs and cellular pathway deregu-
lated in BC cells (MCF7 and MDA-MB-231), as a function of the
delivered dose, we produced Venn diagrams as displayed in Fig. 5.
Overall, common and unique genes were deregulated in BC cells after
proton irradiation using the same dose. In particular, 27, 51 and 70
common genes were activated in BC cells after 0.5, 2 and 9 Gy of pro-
ton exposure, respectively. The eight genes shared between BC cells
exposed to the three doses of proton irradiation used are as follows:
chromosome 9 open reading frame 131 (C9orf131); uncharacterized
protein MGC16142 (MGC16142); ATP-binding cassette, subfamily
A (ABC1), member 10 (ABCA10); inositol polyphosphate-5-
phosphatase (INPP5D); engrailed homeobox 1 (EN1); solute carrier
family 6 (neurotransmitter transporter), member 13 (SLC6A13);
AS1FAM13A antisense RNA 1 (FAM13A); and chromosome 8 open
reading frame 34 (C8orf34).
Figure 4 displays the heatmaps of the hierarchical condition tree
of the above-mentioned eight gene signatures related to proton
irradiation cell response. As known, this is a graphical representation
of data where the individual values contained in a GEP are repre-
sented as colors according to their expression with respect to the
control. Overall, down- and up-regulated genes after treatment are
displayed using blue and red scales, as indicated in the key.
Moreover, the 27, 51–70 and 8 gene signatures, were loaded
into the Reactome tool in order to select the related pathways as
shown in Table 8.
Finally, we decided to confirm and validate the involvement of
genes belonging to the above-mentioned signatures, using an in sili-
co approach by PubMatrix, as described in the literature and also by
Table 6. Top five molecular pathways of deregulated gene data sets of MCF10A, MCF7 and MDA-MB-231 cells treated with
9 Gy
Pathway name Genes found in
GEP list
Entities
(total)
P-value FDR
MCF10A 1 Transcriptional activation of p53-responsive genes 4 6 4.02E-4 1.52E-1
2 Transcriptional activation of cell cycle inhibitor p21 4 6 4.02E-4 1.52E-1
3 RUNX1 regulates transcription of genes involved in differentiation
of keratinocytes
5 11 4.37E-4 1.52E-1
4 TP53 regulates transcription of genes involved in G1 cell cycle
arrest
6 20 1.04E-3 2.7E-1
5 RUNX3 regulates immune response and cell migration 4 10 2.6E-3 5.08E-1
MCF7 1 TP53 regulates transcription of death receptors and ligands 7 18 4.63E-6 3.67E-3
2 TP53 regulates transcription of cell death genes 11 83 2.28E-4 8.99E-2
3 Transcriptional activation of cell cycle inhibitor p21 3 6 1.35E-3 2.66E-1
4 Transcriptional activation of p53-responsive genes 3 6 1.35E-3 2.66E-1
5 Transcriptional regulation by TP53 29 486 4.89E-3 7.2E-1
MDA-MB-
231
1 Interleukin-10 signaling 15 88 4.99E-3 8.85E-1
2 Defective CHST6 causes MCDC1 4 9 5.94E-3 8.85E-1
3 Interleukin-4 and -13 signaling 28 212 6.46E-3 8.85E-1
4 ERBB2 regulates cell motility 5 19 1.82E-2 8.85E-1
5 Apoptosis-induced DNA fragmentation 4 13 2.03E-2 8.85E-1
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our group [31]. In this way, lists of terms, such as gene names, were
assigned to genetic, biological or clinical relevance in a flexible sys-
tematic fashion in order to confirm our assumptions. Bibliographic
relationships between proteins and selected queries such as IR, radi-
ation, cancer, BC, electron, proton and inflammation were analyzed
in order to understand the data and to draw useful conclusions
reported below (Supplementary files 3, 4, 5 and 6).
DISCUSSION
There is a substantial lack of data regarding cancer cell and molecu-
lar responses induced by proton irradiation, which prompted this
work. Moreover, the possibility that proton therapy may be used to
treat BC led us to study this topic in breast cell lines. The identifica-
tion of gene signatures linked to specific radiation regimens, as
reported in this work, could be helpful for the understanding of the
molecular mechanisms linked with the treatment efficacy, allowing
the introduction of biological features in RT planning. In this sense,
for the first time to our knowledge, we have performed molecular
analyses of BC cells exposed to different doses of proton irradiation,
highlighting gene expression signatures related to specific cell lines
and proton irradiation configurations. Data collected here confirm
that radiation effects on cells are heterogeneous and appear to act in
Table 7. Top five molecular pathways of selected gene signatures among MCF10A, MCF7 and MDA-MB-231 cells lines
Pathway name Genes found
in GEP list
Entities
(total)
P-value FDR
(A) Top five statistically relevant pathwaysof the MCF10A 92 gene signature
1 Eicosanoids 3 25 9.14E-4 1.9E-1
2 Fatty acids 3 29 1.4E-3 1.9E-1
3 Acrosome Reaction 1 1 7.42E-3 3.37E-1
4 Glutathione conjugation 3 67 1.41E-2 3.37E-1
5 HDL remodeling 2 24 1.41E-2 3.37E-1
(B) Top five statistically relevant pathwaysof the MCF7 58 gene signature
1 Signal regulatory protein family interactions 3 16 1.03E-4 1.34E-2
2 GABA synthesis, release, reuptake and degradation 2 19 5.07E-3 3.3E-1
3 Synthesis of IP3 and IP4 in the cytosol 2 26 9.26E-3 3.52E-1
4 GABA synthesis 1 2 1.1E-2 3.52E-1
5 NR1D1 (REV-ERBA) represses gene expression 1 3 1.65E-2 3.97E-1
(C) Top five statistically relevant pathways of the MDA-MB-231 265-gene signature
1 Binding of TCF/LEF:CTNNB1 to target gene promoters 2 10 1.89E-2 6.94E-1
2 Repression of WNT target genes 2 16 4.47E-2 6.94E-1
3 Glycogen metabolism 3 43 6.22E-2 6.94E-1
4 Gene and protein expression by JAK–STAT signaling after interleukin-12
stimulation
4 74 7.09E-2 6.94E-1
5 TFAP2 (AP-2) family regulates transcription of growth factors and their
receptors
2 21 7.2E-2 6.94E-1
Fig. 3. Venn diagram of microarray gene sets of MCF7
cells exposed to 0.5, 2 and 9 Gy of proton irradiation.
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a cell line-dependent manner. This may in turn lead to an individua-
lized form of treatment with a significant predictive value.
Dose–response effects were analyzed on the non-tumorigenic
(MCF10A) and tumorigenic BC (MCF7 and MDA-MB-231) cell
lines with different aggressive phenotypes. The SFs obtained showed
different cellular radiosensitivity; in particular, the MCF7 cells
revealed greater sensitivity to proton irradiation than MDA-MB-231
and MCF10A cells, which were more radioresistant (Fig. 1).
We performed Luminex and cDNA microarray gene expression
analyses to study molecules and biological processes activated by
exposure to charged particle beams (using 0.5, 2 and 9 Gy of pro-
tons) on the three breast cell lines. Considering that IR induces sig-
nificant effects on immune system modulation able to drive the
survival/cell death balance and senescence process, we first studied
the cytokine, chemokine and growth factor profiles induced in
MCF10A, MCF7 and MDA-MB-231 cell lines by proton irradiation
(Tables 1–3; Supplementary file 2). These molecules are secreted
by treated normal epithelial and residual BC cells in the tumor
microenvironment, driving the tissue IR response by autocrine and
paracrine mechanisms.
Overall, we investigated the time and dose dependence of cyto-
kine signatures for the three cell lines tested, highlighting some dif-
ferences that we think may also be justified by the different
aggressive phenotypes of the three BC cell lines. Indeed, while
MCF10A cells are strongly affected by the dose effect, since strong
quantitative differences are observable between low (0.5 and 2 Gy)
and high (9 Gy) doses for most of the molecules assayed (see
Supplementary file 2), the MDA-MB-231 cells suffer much less
from the dose effect, since no significant quantitative differences are
observable between the low doses and the 9 Gy dose. In contrast,
for MCF7 cells, an irregular pattern is observed for six out of eight
tested molecules, as only IL-6 and IL-8 appear to be produced in a
time- and dose-dependent manner. In particular, MCF10A cells
subjected to 9 Gy show a polynomial-type increasing trend of
Fig. 5. (A) 27–51 and 70 gene dose-related gene signature of BC cell lines exposed to 0.5, 2 and 9 Gy. (B) Heatmap of the 8
gene signature deregulated in BC cells after all three configuration doses. The individual values contained in a GEP were
represented as colors according to their expression with respect to the control. Overall, down- and up-regulated genes after
treatments were displayed using blue and red scales, as indicated in the key.
Fig. 4. Venn diagram of microarray gene sets of MDA-
MB-231 cells exposed to 0.5, 2 and 9 Gy of proton
irradiation.
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inflammatory molecules, TH1-type, TH2-type, chemokines and
growth factors, although the two chemokines IL-8 and MCP-1 have
been identified as early irradiation markers as their relative increase
is observable as early as 48 h post-treatment, regardless of the dose
delivered within the same time. These two molecules (IL-8 and
MCP-1) and IL-6 are produced in a time- and dose-dependent
manner in MCF7 cells, with peaks observable at 72 h post-
irradiation.
The immune response profile of MDA-MB-231 cells to irradi-
ation was characterized by a stronger activation, in a time-
dependent manner and regardless of dose delivered, of 11 out 17 of
the immunological factors analyzed, compared with to MCF10A
and MCF7 cells. Summarizing, MDA-MB-231 cells showed the
strongest potentially pro-inflammatory profile compared with the
other cell lines analyzed. The inflammatory network seems to be
unbalanced as IL-10, the main anti-inflammatory cytokine, is not
expressed and the IL-4/IL-13 up-regulation is rather limited.
Moreover, the observed strong IFN-γ up-regulation at low and high
doses denotes a TH1-type response activation.
Considering the three immunological profiles, IL-6, IL-8 and
MCP-1 could be considered candidate biomarkers of proton irradi-
ation of mammary epithelial cells.
Interestingly, these results are comparable with those obtained
by our group for the same cell lines following electron beams [17].
However, the immunological profiles of the three different cell lines
do not seem to exert a direct role on cell death increasing during
the time window of this in vitro experiment. On the other hand, it
could be speculated that the release of these molecules can play a
different and specific paracrine role in each patient’s tumor micro-
environment, generating individual long-term effects on tumor pro-
gression and post-treatment sequelae, e.g. local or systemic
inflammation, fibrosis or cell senescence.
Moreover, as graphically displayed, some genes were specifically
deregulated according to the dose delivered (dose-dependent gene
lists), whereas other genes (cell-dependent gene list) were com-
monly deregulated after all the three doses delivered and were prob-
ably linked to BC-specific features (Figs 2, 3 and 4). All the gene
signatures selected in this work are available in Supplementary file
1, whereas Tables 4, 5 and 6 displays the top five statistically signifi-
cant pathways activated in the three cell lines studied in response to
0.5, 2 and 9 Gy, respectively.
In MCF10A cells, a 92 common gene list (Fig. 2) has been iden-
tified to sustain the molecular response to irradiation regardless of
the used dose, which participate in the activation of pathways
Table 8. Top five molecular pathways of BC selected gene signatures
Pathway name Genes found in GEP list Entities (total) P-value FDR
(A) Top five statistically relevant pathways of the 0.5 Gy 27 gene signature of BC cells
1 Reuptake of GABA 1 4 1.01E-2 2.71E-1
2 Digestion of dietary carbohydrate 1 10 2.51E-2 2.71E-1
3 PECAM1 interactions 1 12 0.03 2.71E-1
4 ABC transporters in lipid homeostasis 1 18 4.47E-2 2.71E-1
5 Ephrin signaling 1 19 4.71E-2 2.71E-1
(B) Top five statistically relevant pathways of the 2 Gy 51 gene signature of BC cells
1 Interaction between L1 and ankyrins 3 33 3.09E-4 3.7E-2
2 Thyroxine biosynthesis 2 27 5.11E-3 3.07E-1
3 L1CAM interactions 3 129 1.42E-2 3.86E-1
4 Phase 0—rapid depolarisation 2 47 1.47E-2 3.86E-1
5 VEGF ligand–receptor interactions 1 8 3.08E-2 3.86E-1
(C) Top- five statistically relevant pathways of the 9 Gy 70 gene signature of BC cells
1 Interleukin-35 signaling 2 16 3.65E-3 4.3E-1
2 Extracellular matrix organization 6 329 9.89E-3 4.3E-1
3 Thyroxine biosynthesis 2 27 0.01 4.3E-1
4 Integrin cell surface interactions 3 86 1.23E-2 4.3E-1
5 Amine-derived hormones 2 56 3.88E-2 4.42E-1
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related to inflammation, lipid metabolism and detoxification pro-
cesses, listed in Table 7A.
Regarding MCF7 BC cells, the TP53 pathway appears to drive
the signaling controlling the response to radiation. This finding is in
line with our previous investigations on the MCF7 molecular
response to radiation using electron beams [22]. In these cells, a 58
gene signature is activated regardless of the dose used, and the
genes sustain general pathways, GABA metabolism, transduction
signaling and gene expression regulation, which appear not to be
directly related to such a stress response.
Moreover, for the MDA-MB-231 BC cell line, we also selected
unique and common gene signatures linked to the dose delivered
(Tables 4, 5 and 6). Interestingly, IR is able to activate ERBB2 sig-
naling in the MDA-MB-231 cells; nonetheless, they are HER2– and
classified as triple-negative cells. Furthermore, the activation of
inflammatory-related pathways justifies the great capacity of MDA-
MB-231 cells to release inflammatory molecules in the tumor micro-
environment, as highlighted in this work. Moreover, this behaviour
has been previously noted by our group even in response to irradi-
ation using electron beams, a sign that activation of inflammation is
typical of the IR response for these cells [12]. Through inflamma-
tion, these cells control cell fate balance, senescence mechanisms,
angiogenesis and cell migration, explaining their aggressive pheno-
type and the resistance to the treatments, driving the activation of
intracellular mechanisms able to react to stress and known to be
related to the cell response to radiation, as displayed in Table 7C.
These are involved in regulation of gene expression, WNT signaling,
inflammation and glycogen metabolism.
We also decided to analyze, for the first time to our knowledge,
proton dose-related gene signatures, specific for breast cancer cells
(i.e. MCF7 and MDA-MB-231). Interestingly, we selected 27, 51
and 70 genes that were activated in BC cells after 0.5, 2 and 9 Gy,
respectively (Table 8). Moreover, in order to select specific biomar-
kers of proton cell response, we selected eight common deregulated
genes (8 gene signature) shared among the 27, 51 and 70 gene sig-
natures selected and mentioned above (Fig. 4).
All genes belonging to these signatures were also analyzed by
the PubMatrix tool, in order to search for biological interpretation
through NCBI literature of data obtained from microarray analysis.
In particular, we speculate that these genes could represent spe-
cific biomarkers of proton breast cell response. Among these genes,
no information about the involvement of C9orf131, MGC16142,
FAM13A and C8orf3 genes in the radiation cell response (proton
or other types) is now available in the literature, which requires fur-
ther investigation
On the other hand, limited but promising data were collected
for the other genes of the 8 gene signature. In particular, the
ABCA10 gene codes for a member of the superfamily of ATP-
binding cassette (ABC) transporters, often overexpressed in several
tumors and responsible for the traffic of a wide variety of xenobio-
tics, lipids and metabolic products across the cell membranes. These
proteins were also described as implicated in multidrug resistance,
but no information is available regarding their hypothetical role in
radioresistance processes [32, 33].
The INPP5D gene is a member of the inositol polyphosphate-5-
phosphatase (INPP5) family regulated by AKT signaling and
recently described as involved in the apoptotic process, also during
hypoxia conditions independently of p53 activation [34]. As has
been well described, AKT is able to regulate the survival/death bal-
ance, in response to radiation [35]. In addition, AKT activation in
hypoxic regions of breast tumors has been linked with poor patient
prognosis, whereas AKT inhibition may improve radiotherapy
response in p53-deficient tumors, and for this purpose further stud-
ies are needed to evaluate the role of INPP5D in the radioresistance
process.
The EN1 gene is involved in the development of the central ner-
vous system, and recently was described as a prosurvival transcrip-
tion factor in the basal-like BC type. It is also described as
exclusively overexpressed in some extremely aggressive cancers, also
associated with hypoxia, inflammation and high leukocyte infiltra-
tion [36]. However, no information regarding its role and radiation
exposure is available.
The SLC6A13 gene encodes a neurotransmitter transporter
involved in the uptake of δ-aminolevulinic acid (ALA). ALA-
induced protoporphyrin accumulation is a strategy widely used in
cancer treatment. Its expression was found in some cancer cell lines
and can play a role in enhancing the accumulation of ALA-induced
protoporphyrin [37]. Additional studies are needed in order to
identify its role in the radiation cell response.
Overall, data from immunological signatures and the top five
lists of GEP profiling seem to intersect at some points; nonetheless,
transcriptional and translational levels are not always coincident and
the time windows analyzed are different. In particular, immuno-
logical pathways which varied following radiation among the top
five lists analyzed are: (i) Interleukin 4 and 13 signaling with 23
genes varying in MCF10 exposed to 2 Gy; and (ii) the two anti-
inflammatory pathways: Interleukin 10 and Interleukin 4 and 13 sig-
naling, with 15 and 28 genes varying in MDA-MB-231 exposed to
9 Gy. In addition, in MDA-MB-231, the ‘Gene and protein expres-
sion by Jak–STAT signalling after IL-12 stimulation’ is commonly
different among all the dose configurations analyzed.
In MCF7 cells, the GEP profiling does not involve immuno-
logical pathways, justifying the poor secretion levels of immuno-
logical proteins, whereas in MCF10 and MDA-MB-231 cells the
transcriptional activation of an anti-inflammatory response sustained
by the IL-4/IL-13 loop is still observable 24 h post-treatment, to
balance inflammation generated by IR. Furthermore, the conspicu-
ous IFN-γ release 48–72 h post-treatment by MDA-MB-231 cells
exposed to all the doses is fully explained by the activation of ‘Jak–
STAT signalling after IL-12 stimulation’ 24 h post-irradiation.
In conclusion, as previously described by several authors and
also by our group [12, 13, 38], radiation effects on cells are hetero-
geneous and appear to act in a cell line-dependent manner, and this
behavior is also confirmed in response to proton beam irradiation.
CONCLUSIONS
This work highlighted the molecular response to proton irradiation
of three breast cell lines (the tumorigenic MCF7 and MDA-MB-231
and the non tumorigenic MCF10A), in terms of GEP and secretion
of immunological molecules. The three cell lines studied demon-
strated differential GEP/cytokine profiles after proton irradiation,
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showing a cell line- and dose-dependent type of response to radi-
ation. The immunological signatures are dependent on the dose
delivered (low doses of 0.5 and 2 Gy vs a high dose of 9 Gy) in
MCF10A and MCF7 cell lines, whereas MDA-MB-231 cells show a
strong pro-inflammatory expression profile regardless of the dose.
We selected a specific 8 gene signature which represents a list of
common genes deregulated in response to the doses used and in all
the cell lines analyzed in this work that in our opinion need more
investigation. It can be envisaged that our data could be useful in
the definition of personalized proton therapy protocols in combin-
ation with targeted therapies dedicated to breast cancer.
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